Picture of Ryvu Therapeutics SA logo

RVU Ryvu Therapeutics SA News Story

0.000.00%
pl flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Ryvu Therapeutics Gets Approval For Phase I/II Study Of RVU120 (SEL120) In Spain

Dec 21(Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SAID ON MONDAY THAT THE SPANISH AGENCY FOR MEDICINE AND
MEDICAL
DEVICES (AEMPS) HAS FULLY APPROVED CONDUCTING PHASE I/II STUDY
OF RVU120 (SEL120) IN PATIENTS WITH RELAPSED/REFRACTORY
METASTATIC OR ADVANCED SOLID TUMORS IN SPAIN
    * THE ABOVE APPROVAL ALLOWS TO EXPAND THE STUDY OF RVU120 IN
RELAPSED/REFRACTORY METASTATIC OR ADVANCED SOLID TUMORS BEYOND
POLAND, WHERE ACTIVE ENROLLMENT IS ON-GOING

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM9gpN1ma
 Further company coverage:  RVU.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Ryvu Therapeutics SA

See all news